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Purpose: To evaluate a gradient nonlinearity correction (GNC) program for quantitative apparent diffusion coefficient
(ADC) measurements on phantom and human subject diffusion-weighted (DW) magnetic resonance imaging (MRI) scans
in a multicenter breast cancer treatment response study
Materials and Methods: A GNC program using fifth-order spherical harmonics for gradient modeling was applied retro-
spectively to qualification phantom and human subject scans. Ice-water phantoms of known diffusion coefficient were
scanned at five different study centers with different scanners and receiver coils. Human in vivo data consisted of base-
line and early-treatment exams on 54 patients from four sites. ADC maps were generated with and without GNC.
Regions of interest were defined to quantify absolute errors and changes with GNC over breast imaging positions.
Results: Phantom ADC errors varied with region of interest (ROI) position and scanner configuration; the mean error by
configuration ranged from 1.4% to 19.9%. GNC significantly reduced the overall mean error for all sites from 9.9% to
0.6% (P50.016). Spatial dependence of GNC was highest in the right-left (RL) and anterior-posterior (AP) directions.
Human subject mean tumor ADC was reduced 0.2 to 12% by GNC at different sites. By regression, every 1-cm change
in tumor ROI position between baseline and follow-up visits resulted in an estimated change of 2.4% in the ADC early-
treatment response measurement.
Conclusion: GNC is effective for removing large, system-dependent errors in quantitative breast DWI. GNC may be
important in ensuring reproducibility in multicenter studies and in reducing errors in longitudinal treatment response
measures arising from spatial variations in tumor position between visits.
J. MAGN. RESON. IMAGING 2015;42:908–919.
Diffusion-weighted imaging (DWI) is a noninvasivetechnique used to evaluate tissue cellularity and micro-
structure. Studies in patients with breast cancer have dem-
onstrated that DWI can improve the diagnostic accuracy of
MRI when combined with dynamic contrast-enhanced
(DCE) magnetic resonance imaging (MRI) data,1 and can
also provide information on early treatment-related changes
in tumors in patients undergoing neoadjuvant (presurgical)
chemotherapy (NAC).2 There is interest in establishing
MRI biomarkers of treatment response, and such potential
markers are currently being evaluated in clinical trials of
conventional and targeted therapy. In order for DWI-based
MRI biomarkers to be used robustly for monitoring treat-
ment response, it is necessary to identify, characterize, and
correct sources of measurement variation that may impact
the quantitation of MRI-measured biomarkers.3
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A significant source of bias in diffusion measurement
is the inherent nonlinearity of the imaging gradients in
MRI systems.4–7 This gradient nonlinearity (GN) is a well-
known characteristic of the gradient design, and results in a
nonlinear and systematic spatial distortion of the encoded
image known as gradient warping or "gradwarp".8,9 The
magnitude of GN generally increases with distance from the
magnet isocenter and can be efficiently described by just a
few spherical harmonics coefficients.8,9 Gradwarp correction,
a feature offered by all clinical MRI vendors, interprets these
coefficients to perform the necessary local image interpola-
tion and scaling needed to create a spatially accurate MR
image. However, GN also affects diffusion-encoding, result-
ing in a systematic and spatially-dependent bias of the
diffusion-encoding b-value or b-matrix.10 These errors in
diffusion-encoding will result in spatially dependent inaccur-
acy of diffusion measurements. The extent of GN varies
between MRI systems from the same vendor 7 and between
systems from different vendors,11 and this directly results in
lower concordance between measurements in multisite stud-
ies and worsened reproducibility in monitoring longitudinal
changes if multiple scanner configurations are used. In bilat-
eral breast DWI, large spatial offsets from isocenter are
inherent to the prescribed field-of-view (FOV) and vary sig-
nificantly between different receiver coil designs; hence
breast DWI is highly susceptible to bias resulting from GN.
As an example, regional variations in apparent diffusion
coefficient (ADC) of breast tissue recently reported by Par-
tridge et al 12 may be attributed in part to GN effects.
Correction of GN effects in DWI works by account-
ing for nonlinearity of the gradient fields during calcula-
tion of ADC. Early work on GN included correction in
single-directional ADC imaging,5 and in multi-directional
diffusion tensor imaging where the full diffusion tensor
was used.4 However, the recent increase in demand for
quantitative, large FOV diffusion imaging in oncology
13,14 has focused primarily on DWI acquisitions that typi-
cally use only one to three gradient-encoding directions,
which are insufficient to solve for the entire diffusion ten-
sor. Hence, simplified DWI-optimal GN correction techni-
ques have recently been developed 6,7 that allow for
correction without need to acquire the full tensor dataset.
Additionally, the work from Tan et al 7 found it was neces-
sary to also correct for confounding spatially varying signal
bias effects in order to demonstrate improved accuracy and
interscanner reproducibility of ADC. Such effects include
the concomitant field arising from dual-spin-echo diffusion
preparation sequences,15 and image distortion related to
eddy-current and susceptibility. Therefore, GN correction
(GNC) schemes that account for both limited-
directionality DWI and other confounding nonlinearity
effects will be needed to provide accurate and reproducible
DWI biomarkers.
GN effects are of particular concern in longitudinal,
multicenter trials such as treatment response trials for breast
cancer. Interscanner variability exists even between different
model scanners from the same manufacturer, and will pres-
ent difficulties when attempting combined quantitative anal-
ysis across the trial. Furthermore, while spatially dependent
GN effects can be mitigated by choosing metrics based on
percent change in ADC over time rather than absolute value
at a given timepoint, the spatial variability of the GN bias
will still result in errors in these measurements due to posi-
tional changes between visits. The purpose of this study was
to evaluate a GNC program for ADC measurements on
phantom and human subject DW MRI scans in a multicen-
ter breast cancer treatment response study.
MATERIALS AND METHODS
GNC in DWI
GNC in diffusion imaging is typically described as a correction of
the derived diffusion metrics, such as ADC and fractional anisot-
ropy (FA). These diffusion metrics can in turn be derived from the
diffusion tensor D, which is a three-by-three matrix with six inde-
pendent scalar components:
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Conventionally, D is solved by a system of linear equations
relating D to the diffusion-encoded signal Si, the nondiffusion-
encoded signal S0, the encoding scalar b-value b, and the normal-
ized 3D gradient vector gi. Without GNC, gi is the same for every
pixel. In diffusion tensor imaging (DTI), six or more gi gradient
vectors are used to acquire the resulting set of signals Si, sufficient
to mathematically solve for D. With GNC, gi varies on a pixel-by-
pixel basis, and can be obtained by decoding the spherical harmon-
ics to obtain the pixel-based gradient vector g0i.
7 In this setting, the
familiar Stejskal-Tanner equation ln(Si/So)5 –biD can be written
in matrix form to solve for D:
ln ðSi=S0Þ52bg0iTDg0i: (2)
However, in DWI where as few as just one gradient vector
may be used, there are insufficient gradient directions or equations
to solve for D. Hence, GNC in one-directional DWI reverts to the
scalar version of the Stejskal-Tanner equation, whereby the GN-
modified b-value b0i is effectively:
b0i5bi
kg0ik2
kgik2
: (3)
Therefore, the b-value correction of Eq. (3) may be used in
nontensor-based DWI, where fewer than six gradient vector direc-
tions are available. Another situation where the scalar b-value cor-
rection may apply is when only trace (also known as combined)
diffusion images are available, whereby diffusion images with the
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same b-value from multiple gradient directionalities are combined
to form a single image and the individual diffusion images are not
stored for postprocessing. The b-value correction may also be used
to directly obtain a b-value-corrected signal:
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Alternatively, in three-direction DWI a system of linear
equations can still be used to estimate the diffusion tensor. This is
done by limiting the number of eigenvalues (or singular values) in
the eigenvalue (or singular value decomposition) of Eq. (2) to
three, instead of using all six eigenvalues as in the DTI case. In
cases where multiple b-values are used in DWI, the number of
eigenvalues is limited to the number of gradient directions per
b-value (one to three).
In this work, a GNC program (GE Global Research, Nis-
kayuna, NY) 7 using fifth-order spherical harmonics coefficients
was used to retrospectively generate ADC maps from the acquired
diffusion images. Confounding effects on the diffusion signal due
to concomitant field resulting from the use of dual-spin-echo diffu-
sion preparation 15 were also accounted for. In cases of three-
directional DWI data where diffusion data from individual gradi-
ent directions were available, Eq. (2) was applied (limiting the
eigenvalues to three in the case of three-directional DWI). In cases
where only the trace (combined) diffusion data was available, the
b-value correction of Eq. (3) was used. Equation (4) was also used
to generate b-value-corrected images.
Study Imaging Sites and Equipment
Configurations
Five imaging sites participating in the ACRIN 6698 substudy of
the I-SPY 2 TRIAL (http://ispy2.org) and using GE Healthcare
MRI equipment were included in this study. All imaging studies
were performed on 1.5T HDx scanners (GE Healthcare, Wauke-
sha, WI) using receive-only breast coils. Details of the equipment
configurations for the five sites are given in Table 1. Three differ-
ent gradient system configurations were represented (A through C)
with different maximum gradient amplitudes (Gmax5 40mT/m
(A), 22mT/m (B), 33mT/m (C)) and maximum gradient slew rates
(SR5 150mT/m/ms (A), 77mT/m/ms (B), 120mT/m/ms (C)).
Different Gmax and SR, as well as differences in the site-specific
acquisition protocols, result in different echo times (TE) and echo
spacing (ESP), as shown in Table 1, and result in different distor-
tion effects due to the EPI readout. Two different eight-channel
receiver coil models were used across the five sites, a Sentinelle
model (Invivo, Gainesville, FL) and a GE model (GE Healthcare).
The primary difference between coils was the position of the center
of the FOV in the anterior-posterior (AP) direction with respect to
the magnet isocenter. Equipment configurations for the human
scans were similar to those used for the phantom studies (Table 2).
Site 2 was not included in the human studies for this work as no
patients had been scanned on GE Healthcare scanners.
Phantom Design and ACRIN 6698 DWI Quality
Control Procedure
Breast-sized diffusion phantoms were constructed from 1.5-L,
11 cm diameter cylindrical plastic containers. A single 2.9 cm
diameter thin-walled plastic measurement tube filled with distilled
water was thermally insulated at both ends and held vertically
within each container by closed-cell foam support rings affixed to
the bottom and removable top of the container (Fig. 1). A pair of
phantoms and phantom preparation instructions were provided to
each site for the purpose of completing standardized qualification
quality control (QC) scans for the ACRIN 6698 trial (see http://
www.acrin.org/6698_protocol.aspx for protocol details). At least 1
hour prior to scanning, the space surrounding the measurement
tube was filled with a mixture of crushed ice or ice cubes and
water. Each phantom was placed in a foam insulation sleeve and
plastic bag to keep condensate away from MRI components.
Once at thermal equilibrium at 0C, water within the measure-
ment tube will have a known diffusion coefficient of 1.1 3 1023
mm2/s.16
The diffusion protocol for all phantom scans was a three
orthogonal-direction DWI with four b-values of 0, 100, 600, and
TABLE 1. Equipment Configurations for Phantom Study
Site Gradient
system
Rx coila Echo
time
(msec)
Echo
spacing
(ms)
Image
dimension
(pixels)
FOVb center
in L/R (-/1)
direction (mm)
FOVb center
in A/P (-/1)
direction (mm)
Individual
directions
available
1 A 8ch, Sentinelle 68.5 664 1603160 20.1 267.3 Yes
1 B 8ch, Sentinelle 95.4 912 1603160 20.1 267.3 Yes
2 C 8ch, Sentinelle 98.3 748 1603160 12.6 281.1 No
3 C 8ch, GE 116.3 884 2563256 16.2 22.4 No
4 A 8ch, GE 99.3 784 2563256 17.2 117.9 No
5 A 8ch, GE 96 664 1603160 10.3 110.5 No
aReceive coils: Sentinelle (Invivo, Gainesville, FL); GE (GE Healthcare, Waukesha WI).
bFOV: field of view.
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800 s/mm2, using a single-shot EPI sequence. Thirty 4-mm thick
axial slices with a 32 cm FOV were acquired providing full cover-
age of the phantoms. Software and clinical workflow differences
between the five sites resulted in minor variations in how the
acquisition protocol was performed. The scanner software
employed at sites 2, 3, and 4 required three separate dual b-value
scans of b5 (0,100), (0,600), and (0,800) s/mm2, acquired consec-
utively at the same TE, while sites 1 and 5 used a single acquisi-
tion four b-value protocol. Also, the individual diffusion images
from all three directions were available from Site 1, while Sites 2–5
provided only combined (trace) images.
The ACRIN 6698 DWI QC phantom scan procedure
required four sequential DWI acquisitions over 12 minutes,
which were analyzed at ACRIN Core Labs (ACRIN and University
of Michigan) for site certification. Stability in ADC values meas-
ured over this interval was evidence that the phantom achieved
thermal equilibrium. For the current study, selected protocol com-
pliant scans from thermally stable acquisitions from each site were
analyzed retrospectively.
Human Studies
The effects of GNC on human subject ADC measurements were
evaluated using DWI data from the I-SPY 2 study collected at sites
using GE scanners. I-SPY 2 enrolled patients with locally advanced
breast cancer, screened to identify those with high risk of recur-
rence according to the Mammaprint 70-gene signature 17 and
receptor status (estrogen receptor and Her2). All patients gave
informed consent following explanation of the planned procedures.
Subjects received up to four MRI studies: pretreatment (MR1),
early-treatment (MR2, following 3 weeks of Paclitaxel), interregi-
men (MR3, after 12 weeks Paclitaxel), and presurgery (MR4, fol-
lowing all NAC treatment). The MR1 and MR2 visits were used
in this study evaluating GN effects. Fifty-four patients, mean age
50 years (age range 32–71 years, excluding patients from Site 4
for which date of birth data were not available), with analyzable
diffusion scans at both MR1 and MR2 were included, as indicated
in Table 2.
All patients enrolled in the I-SPY 2 TRIAL receive a bilateral
DWI scan in addition to standard T2-weighted and 3D high spa-
tial resolution (DCE) imaging. Those enrolled in the ACRIN
6698 substudy (patients from Sites 1, 4, and 5) were scanned with
the four b-value protocol (b5 0, 100, 600, and 800 s/mm2) as
described in the previous section. Patients from Site 3, which was
not participating in ACRIN 6698, received a single dual b-value
DWI scan (b5 0, 800 s/mm2) as prescribed by the I-SPY 2 proto-
col. Differences between the phantom and human DWI protocols
included variations of the image dimension (Sites 3, 4, and 5) and
a significant reduction in TE (Site 5) as shown in Tables 1 and 2.
The FOV for human scans ranged from 30–38 cm in order to
provide full bilateral coverage of the breasts.
Analysis
MRI DICOM images were transferred to a local analysis archive,
either directly from local PACS or from other sites via the TRIAD
program (ACRIN, Philadelphia, PA). All processing except the
GNC program was done with in-house software written in the
IDL (Exelis Visual Information Solutions, Boulder, CO) program-
ming language. Monoexponential uncorrected ADC maps were
generated for each diffusion acquisition, using a linear least-squares
fit to the log of the signal intensity for the four b-value series and
a simple two-point calculation for two b-value series. Special proc-
essing was required for the human subject scans from Sites 2 and
4, where multiple-series matched two b-value acquisitions
[(0,100 s/mm2), (0,600 s/mm2), (0,800 s/mm2)] were used to
acquire a four b-value dataset. These series were automatically
identified and the DICOM headers were automatically checked to
ensure that no changes to the pertinent scan parameters, other
than b-value, were made between the individual series. The
multiple-series scans were combined into a single four b-value
series consisting of all b>0 images and a single average T2 image
created from the three b5 0 images. DICOM attributes were then
TABLE 2. Equipment Configurations for Human Study
Site Gradient
System
Rx Coil Echo
Time (ms)
Echo
Spacing
(ms)
Slice
Thickness
(mm)
High
b-values
(s/mm2)
Subjects Image
Dimension
Individual
directions
available
1 A 8ch, Sentinelle 67.9 648 4 100,600,800 28 1603160 Yes
3 C 8ch, GE 94.6 764 5 800 5 192x192 No
4 A 8ch, GE 96.5 704 5 100,600,800 11 1283128 No
5 A 8ch, GE 61.5 620 5 100,600,800 10 1923192 No
FIGURE 1: Breast diffusion phantom: (a) unfilled phantom
showing measurement tube, (b) typical central axial T1-
weighted MRI showing the center tube surrounded with an ice/
water mixture.
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set to allow processing of the combined series by both the ADC
mapping software and the GNC program. Since no significant
deviation from monoexponential diffusion behavior was expected
in free water, the phantom scans from these sites were analyzed as
individual two b-value acquisitions and the b5 0,800 s/mm2 series
results are presented here.
Spatial variations in phantom ADC maps were evaluated
with line intensity profiles and ROI analysis. To determine the AP
direction (y-axis) variations in ADC, line profiles (of 5-voxel
width) were obtained along the center of the inner phantom tubes.
In addition, four rectangular ROIs, 1.5 3 1.0 cm2, were evenly
distributed in the AP direction along the middle slice of each
phantom image. Phantom and breast coil geometries restricted
phantom positioning to a vertical orientation, thereby limiting
evaluation of variations in the superior-inferior (SI) direction (z-
axis). SI variations in absolute ADC error over a 61 cm range
were evaluated with small (1 cm diameter) circular ROIs placed on
all slices intersecting the central phantom tube. ADC error could
not be found in the ice1water region outside the center tube due
to the lack of homogeneous, artifact-free regions. In images where
there was sufficient signal in the outer volume, the circular ROIs
were extended to map the GNC effects at larger SI offsets by cal-
culating the percent change in measured ADC with GNC.
For the human subject scans, areas of tumor were initially
identified on subtraction images from the DCE acquisition. As
image misregistration did not allow for direct transfer of ROIs
from the DCE to the diffusion images, tumor ROIs were drawn
manually by trained research associates with 2–5 years of experi-
ence, following a standard operating procedure defined by mem-
bers of the ACRIN 6698 study protocol team. ROIs were defined
on the diffusion scans as regions hyperintense on the high-b value
DWI and hypointense on the ADC map. The DCE images were
used for reference to ensure correct anatomical location within the
breast. Regions of tumor necrosis were excluded based on high
intensity on the ADC maps. ROIs were drawn on contiguous slices
to include all tumor volume, and these single-slice regions were
combined into a single 3D whole-tumor ROI. ROI positions were
characterized by a single 3D centroid (center-of-gravity) position
relative to magnet isocenter and an ROI extent along each axis.
ROIs for scans from MR1 and MR2 were generated independently.
The whole-tumor ROI for each diffusion series was evaluated for
mean, median, standard deviation (SD), and SD/mean for ADC
maps with and without GNC. In addition, all patients for each
equipment configuration were analyzed together to generate nor-
malized combined ADC histograms for all ROI voxels from all
patients at MR1 and MR2 for each equipment configuration, with
and without GNC, using a bin size of 1 3 1025 mm2/s. Early
treatment response in ADC (DADCET), defined as the percent
change in mean tumor ADC between MR1 and MR2, was calcu-
lated for both uncorrected and GNC ADC data.
Statistical Analysis
Statistical analysis was performed in R (R Core Team (2014). R: A
language and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. URL http://www.R-
project.org). A Wilcoxon signed rank test was used to assess the
change in phantom ADC error with GNC within and between
configurations. Paired and two-sample t-tests were used on the
human subject data to evaluate differences between GNC and
uncorrected tumor ADC measurements and DADCET within and
between configurations. Pearson’s correlation was used to assess the
strength of relationship between GNC changes in DADCET with
changes in the ROI position between visits. All tests were per-
formed two-sided with significance level alpha5 0.05.
FIGURE 2: ADC maps of ice-water phantoms from Site 1 (a,b) and Site 5 (c,d). Left images (a,c) are original data, right images
(b,d) from GNC data. Window/level settings are matched for all four images at 1.0 3 1023 mm2/s window and 1.2 3 1023 mm2/s
level. For the Site 1A configuration, GNC resulted in a noticeable change in ADC level and homogeneity, as evidenced by the
lower overall ADC and the reduction in ADC gradient from top to bottom in the center tube as seen in (b) as compared to (a).
Site 5 images are more typical, showing little visual evidence of GN effects other than a general decrease in intensity in the ADC
map when calibrated window/level settings are used. As seen here, the degree of spatial distortion varied between sites.
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RESULTS
Phantom Results
Typical phantom ADC maps from two sites without and
with GNC are shown in Fig. 2. Identical window and level
intensity settings, corresponding to 1.0 3 1023 mm2/s win-
dow and 1.2 3 1023 mm2/s level, were used for all four
images. Qualitative differences were noted between uncor-
rected and GNC maps from Site 1 (Fig. 2a,b), with distinct
global decrease in ADC with GNC along with elimination
of the gradient towards higher ADC values in the anterior
end of the phantom. Effects of GNC were subtler on the
other configurations, generally not visible in qualitative
comparisons unless display window and level settings were
carefully set to enhance the decrease in ADC with GNC.
The degree of image distortion varied considerably between
sites, as illustrated in the figure.
Figure 3a shows typical ROIs drawn at different AP
positions in the two ice-water phantoms, with ADC results
plotted in Fig. 3b (left phantom) and Fig. 3c (right phan-
tom). Site 1 results shown are for the higher speed gradient
system A, as described below. The ADC errors (percent dif-
ference from 1.1*1023 mm2/s) were reduced by GNC in all
sites and in 37 of 40 ROIs. The larger offset from isocenter
in the AP direction when using the Sentinelle coil resulted
in a greater increase in uncorrected error in the more ante-
rior ROIs at Sites 1 and 2 when compared to Sites 3–5
using the GE coil. Mean percent error across all eight ROIs
and paired Wilcoxon signed rank test results for each equip-
ment configuration are given in Table 3. Site-to-site differ-
ences in the magnitude of ADC error before correction
were large; ranging from Site 1 with 19.9% mean error, to
site 3 with 1.4% mean error. The range of mean ADC error
was reduced by GNC to a maximum 3.9% (Site 1B) to
22.0% (Site 5). Table 4 shows results for the intersite Wil-
coxon signed rank tests. The maximum site-to-site differ-
ence in the estimated mean value for the ADC error was
18% for uncorrected data, reduced to 3.9% after GNC.
The Site 1 scanner was a dual gradient mode model
that allowed for gradient strength/slew-rate performance and
gradient nonlinearity effects to be compared on the same
MRI scanner (gradient systems A and B). Figure 4a,b shows
corrected ADC maps from the left phantom (left
offset5 10 cm) for gradient systems A and B, respectively.
The system B map appears to have more distortion and
increased ADC variability. Figure 4c,d shows the ADC pro-
files along the AP direction for the two gradient modes with
and without GNC for the left and right phantoms, respec-
tively. While the system B displays smaller ADC errors
using uncorrected images, the higher speed system A mode
showed much lower errors after correction. There were also
more artifacts with gradient mode B due to the longer echo
time and echo spacing, as illustrated by the oscillatory
behavior of the ADC plot for the left phantom between
positions A10 and A50. As the shorter TE images were
judged superior for clinical image quality, all further investi-
gations were limited to gradient mode A.
Due to the phantom geometry only a relatively small
(2 cm) range of positions within the central tube was test-
able against a known diffusion value in the superior–inferior
(z-axis) direction. Where sufficient signal was present in the
outer phantom region the relative change in ADC with
GNC was measured over a larger 7.2 cm range. Figure 5a,b
FIGURE 3: ROI analysis of original and GNC phantom ADC
maps from five imaging sites: (a) typical ROI placement (Site 5
image shown); (b,c) mean ROI ADC error (percent difference
from the known value of 1.1 1023 mm2/s) for left and right
phantoms, respectively. Hatched bars show the original data
ADC, solid bars show the GNC data ADC. Labels for each pair
of data points give the anterior/posterior position of the ROI in
mm, while the subtext gives the mean right/left offset of the
four ROIs. AP positions illustrate the more vertically centered
position for the coil used at Sites 3–5, while the generally
smaller RL offsets in the right phantom may be due to image
distortions. Site 1 results shown are for gradient system A.
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shows sample images with ROIs from two slices in the left
phantom from Site 1A (original data, no GNC); Fig. 5b
showing the small signal voids from the solid phase crushed
ice. Figure 5c shows the mean ADC percent error by site
for ROI 2L (center ROI, left phantom) for each of the six
slices measurable in the center tube (slice positions 21.0 cm
to 1.0 cm, 4 mm slice thickness). The residual errors for
the Site 2 data were due mainly to artifacts in the images
and derived ADC maps. As seen in Fig. 5c, both Site 4 and
5 had apparent oscillations in ADC between slices, the mag-
nitude of which sometimes was comparable to the GNC
correction. Due to the small number of slices, statistical tests
of this oscillation were inconclusive (eg, Wilcoxon sum rank
test comparing odd to even slices: P5 0.1, 90% confidence
interval [CI]5 [0.686 2.241] for Site 4). Figure 5d shows
the variation in the percent change of ADC with GNC
across an 18 slice (7.2 cm) range for Sites 1A, 2, 4, and 5.
Sites 1A, 4, and 5, all running gradient system A, had com-
parable changes in ADC correction percentage over this
range of z-axis positions; the GNC effect on ADC typically
decreasing 1.4% to 2.5% between z5 0 and z563 cm, as
shown by the curvature of the plots in Fig. 5d. Site 2 (gra-
dient system C) showed less variation with z position, with
a maximum change of 0.9% over the same range of
positions.
Human Subject Results
MRI-visible tumor volumes varied greatly between patients,
as evidenced by ROI volumes from 0.69 cc to 291 cc at
visit MR1 (median5 7.94 cc) and from 0.17 cc to 110 cc
at MR2 (median5 5.61 cc). Maximum in-plane extent (RL
or AP direction) varied from 1 cm to 11 cm. Figure 6
TABLE 3. Phantom ROI Measures: Paired Wilcoxon Sum Rank Test on Percent ADC Error in 8 Rectangular ROIs
Uncorrected GNC
Est. mean
ADC error
Lower
95% CI
Upper
95% CI
P-value Est. mean
ADC error
Lower
95% CI
Upper
95% CI
P-value
Site 1A 19.9 15.02 25.50 0.008 0.9 20.58 3.36 0.641
Site 1B 9.1 6.15 12.15 0.008 3.9 20.31 7.76 0.055
Site 2 7.4 2.93 11.95 0.016 2.3 21.44 5.29 0.109
Site 3 1.4 20.18 3.26 0.078 1.1 20.52 2.90 0.250
Site 4 11.7 8.54 15.17 0.008 0.8 20.99 2.64 0.383
Site 5 9.1 7.32 10.98 0.008 22 22.7 21.08 0.008
TABLE 4. Intersite Comparisons of Phantom ROI Measures: Paired Wilcoxon Signed Rank Test
Uncorrected GNC
Sites Dmeana Dlocationb Lower
95% CI
Upper
95% CI
P-value Dmean Dlocation Lower
95% CI
Upper
95% CI
P-value
1A to 2 12.5 12.6 8.7 16.2 0.008 1.4 22.0 25.6 2.9 0.383
1A to 3 18.5 18.0 14.2 23.3 0.008 0.2 21.0 22.7 3.3 0.461
1A to 4 8.2 6.7 4.4 12.0 0.008 0.1 0.1 22.8 3.2 0.945
1A to 5 10.8 10.4 6.6 16.1 0.008 2.8 2.0 1.5 5.8 0.008
2 to 3 6.0 5.7 1.2 9.9 0.008 1.2 1.3 22.0 4.6 0.313
2 to 4 4.3 24.0 29.4 0.1 0.055 1.6 1.6 22.4 4.9 0.250
2 to 5 1.7 21.8 26.6 1.8 0.441 4.3 3.9 0.2 7.5 0.039
3 to 4 10.3 210.0 213.8 26.7 0.008 0.3 0.3 21.6 2.7 0.844
3 to 5 7.6 27.4 29.3 26.1 0.008 3.0 3.0 1.7 4.4 0.008
4 to 5 2.6 2.8 20.1 5.0 0.055 2.7 2.8 0.8 4.7 0.016
aDmean: Difference in mean ADC error.
bDlocation: Difference in Wilcoxon pseudo-median.
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illustrates the range of tumor ROIs analyzed, from a rela-
tively small solid tumor (Fig. 6a) to a large tumor with
necrotic core (Fig. 6b). Figure 6c,d shows maps of the corre-
sponding percent changes in ADC with GNC for these two
exams. Despite the large extent of the tumor in Fig. 6b,
which results in a large variation in size of the GNC effect
across the ROI, the relative spread of the ADC distribution
as measured by the standard deviation divided by the mean
did not change much with GNC (original data: mean
(SD)5 1257 307 mm2/s, SD/mean5 0.24; GNC data:
mean (SD)5 1100 272 mm2/s, SD/mean5 0.25). This was
FIGURE 4: Comparison of gradient modes A and B on the Site
1 scanner. (a,b) Left phantom GNC ADC maps for the two gra-
dient modes. Increase in distortion and artifacts are visible in
the slower speed gradient B image. (c,d) ADC error profiles
along posterior-to-anterior lines as indicated by the arrows in
(a,b) for left (c) and right (d) phantoms. Uncorrected (solid lines)
and GNC (dashed lines) are shown for gradient system A (thick
lines) and B (thin lines).
FIGURE 5: Superior-inferior variations in GNC in the ice water
phantom. Axial slice images of the left phantom showing circu-
lar ROIs (a) 1.2 cm superior offset at edge of the center tube
and (b) 3.2 cm superior offset in the mixed ice-water region. (c)
Percent error in ADC for the middle ROI, left phantom, for six
slices (2.4 cm) within the central tube for each site. Uncor-
rected data are shown in cross-hatched bars, GNC data in solid
bars. (d) Variation in percent change in ADC with GNC across
18 slices (7.2 cm) for each ROI in the left phantom for Sites 1,
2, 4, and 5. Site 3 used larger blocks of ice, resulting in large
signal voids preventing z-axis correction measurements outside
of the central tube. Labels give AP position of the ROI. Circles,
squares, and triangles represent ROIs 1L, 2L, and 3L,
respectively.
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true for almost all of the cases investigated, indicating that
for individual cases biological variations across the whole-
tumor ROI used in this study appear to be larger than the
GNC size variations.
Normalized combined ADC histograms for Sites 1, 4,
and 5 all showed a noticeable GNC effect, although the Site
5 effect was small, while Site 3 showed essentially identical
ADC distributions with and without GNC. Statistical
results for the changes in ADC with GNC for each configu-
ration and between configurations are given in the top sec-
tion of Table 5, for the baseline MR1 visit. All sites showed
a statistically significant decrease in ADC with GNC
(P< 0.01), but the reduction at Site 3 was too small to be
of practical significance (20.2%5 –2.2*1026 mm2/s). MR2
data is not shown but was very similar, with a maximum
change with GNC of 212% (2146*1026 mm2/s) for Site
4. Little change in the relative widths (SD/mean) of the
tumor ADC distributions was seen with GNC, although
Sites 1 and 5 did have small percentage decreases at both
visits: Site 1 SD/mean changed 21.7% and 25.7%, Site 5
22.3% and 26.4%, for MR1 and MR2, respectively. How-
ever, Site 4 SD/mean increased slightly, 1.3% at MR1 and
2.9% at MR2, and Site 3 showed no change. Intersite com-
parisons of the percent change in ADC with GNC are given
in the second section of Table 5. The GNC effect at Site 3,
running gradient system B, was significantly different from
each of the 3 sites running gradient system A.
Results from t-tests on the difference in mean early
treatment response in ADC (DADCET) with and without
GNC are given in the third section of Table 5. Mean
DADCET across all patients was effectively unchanged by
GNC: a 9.42% (SD5 15.7) increase in ADC using uncor-
rected data compared to 9.41% (SD5 15.2) with GNC
(P5 0.96, 95% CI5 [–0.58, 0.56]), and no site showed a
statistically significant change with GNC. However, there
were changes of up to approximately 64% (mean (SD)
absolute change 1.66% (1.40%)) in individual patient
DADCET values with GNC due to shifts in the tumor ROI
position or extent between MR1 and MR2. Figure 7a shows
the difference in DADCET with and without GNC plotted
against the difference in the in-plane ROI centroid position
(ie, off-axis distance from isocenter) between the two visits.
A linear regression (dotted line) led to an estimated increase
of 2.36% (95% CI5 [2.05, 2.67]) in measured DADCET
for each 11 cm change in position of the tumor ROI
between visits. The positional changes observed were rela-
tively small (mean (SD) change 0.66 (0.54) cm) so that
expected changes based on the regression would typically
FIGURE 6: Sample slice images with tumor ROIs showing (a) a small solid tumor (Site 3, GE coil, ROI volume54.27 cc, size52.36
3 2.64 3 1.5 cm3, in-plane position58.68L, 1.22A) and (b) a large ring-shaped tumor around a necrotic core (Site 1, Hologic coil,
ROI volume5291 cc, size510 3 11.5 3 8.9 cm3, in-plane position59.9R, 3.8A). (c,d) The corresponding color-coded maps of
the percentage change in ADC resulting from GNC.
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not be higher than 4%. The corresponding estimated
Pearson’s correlation of r5 0.91 (95% CI: 0.85, 0.95) indi-
cates that position shifts of the tumor ROI can explain the
bulk of the GNC variation in measured DADCET. A similar
analysis of change in DADCET versus z-axis (S-I direction)
position changes between visits led to an estimated 0.02%
(CI 20.31, 0.36) increase in measured DADCET for each
11 cm change in the z-axis, shown in Figure 7b (mean
(SD) z-axis position change 1.51 (1.29) cm). The corre-
sponding estimated correlation was r5 0.02 (95% CI
20.26, 0.30), altogether indicating that GN changes due to
z-axis shifts in position have at most a limited effect on
ADC treatment response measures. Note that all percentage
changes in DADCET given refer to absolute changes in the
DADCET measurement, not percentage changes of that
measurement.
DISCUSSION
In this study we examined the effects of GNC on ADC
measurements in a breast cancer multisite trial setting using
phantom and human MRI data. Using a known ADC refer-
ence phantom (water at 0C), we found a wide range of
errors in uncorrected scans. These errors were highly
dependent on the gradient system and measurement posi-
tion. In geometries typical for clinical breast imaging the
uncorrected errors in ADC increased with distance from the
magnet isocenter, ranging from over 30% to less than 1%.
The ADC errors were in almost all cases positive, implying
a higher true b value than the nominal programmed b value
for the acquisition. This was expected, given the large lateral
offsets (8–10 cm) for all ROIs examined and the known
GN trend to increase gradient strength with increased lateral
or vertical displacement from the isocenter. In 37 of 40
phantom ROI locations GNC reduced ADC error, in many
cases dramatically, indicating a robust correction for GN
errors.
Large lateral offsets are unavoidable for breast imaging
in horizontal bore clinical MRI scanners, but offsets from
isocenter in the AP direction can also be sizeable and
dependent on the breast coil used. A recent study of normal
breast using DTI found variations in breast tissue ADC
along the AP direction,12 which parallel our observations of
TABLE 5. Human Subject Results
Mean ADC MR1
(x1026 mm2/s) paired
t-test by site
Estimated Dmean
with GNC
Lower 95% CI Upper 95% CI P-value
Site 1A 2135.6 2155.6 2115.5 4.7*10214
Site 3 22.3 23.6 20.9 0.0096
Site 4 2130.5 2179.6 281.4 0.0001
Site 5 291.4 2126.1 256.6 0.0003
% change ADC with
GNC inter-site comparison
2 sample t-test
Difference in estimated
means (%)
Lower 95% CI Upper 95% CI P-value
Site 1A to Site 3 11.08 212.46 29.71 5.1*10216
Site 1A to Site 4 20.14 23.84 4.12 0.9407
Site 1A to Site 5 24.04 1.24 6.84 0.0079
Site 3 to Site 4 10.94 214.78 27.11 8.2*1025
Site 3 to Site 5 7.04 29.63 24.45 0.0002
Site 4 to Site 5 23.90 20.44 8.25 0.0751
DADCET (% change)
paired t-test by site
Estimated Dmean
with GNC
Lower 95% CI Upper 95% CI P-value
All patients 20.01 20.58 0.56 0.94
Site 1A 0.14 20.78 1.07 0.75
Site 3 20.04 20.16 0.07 0.35
Site 4 20.86 22.03 0.30 0.13
Site 5 0.54 20.77 1.85 0.37
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increasing ADC with increasing anterior offset in the phan-
tom scans. This effect was seen most clearly in data from
sites using the Sentinelle coil, which positioned the phan-
tom more anterior (6 cm) than the GE coil. In all cases
GNC effectively removed these variations, leaving no appa-
rent systematic trends in ADC error with AP position. It
was not clear in our study whether the observed difference
in AP position between the two coil types was only due to
phantom-specific positioning differences or would carry over
into human imaging. The observed difference in mean AP
tumor ROI position for the in vivo scans, 1.2 cm, was
much smaller than the 6 cm difference observed in the
phantom scans, but the relatively small sample size and large
variability in breast size and tumor position within the
breast do not allow us to draw any conclusions about sys-
tematic biases in positioning between the two coil designs.
Longitudinal (superior/inferior) direction offsets appear
to be the least significant source of GN errors of the three
axes in breast DWI. While the phantom geometry did not
allow precise mapping of ADC error beyond about 61 cm
from the isocenter in the SI direction, we did map the
GNC effect out to 63.2 cm and observed a maximum
change in the ADC correction factor from GNC of 2.5%
in this range. Given the limited extent of SI-direction avail-
able for measurement, our observations were consistent with
that reported elsewhere on other scanners.11 Qualitatively,
we observed that the GNC correction was also able to
restore ADC uniformity in the SI direction.
We found marked differences in the system character-
istics between the two gradient modes on the "dual-speed"
scanner, illustrating tradeoffs that must be made in system
design between speed and linearity, and thereby in imaging
use between qualitative image quality and quantitative accu-
racy. While gradient system A, with higher SR and Gmax,
provided clearly superior qualitative image quality by allow-
ing lower TE and ESP to be prescribed, the high GN errors
resulted in a failure of the qualification standards for the
ACRIN 6698 study. In contrast, gradient system B provided
sufficient quantitative ADC accuracy, but did not provide
sufficient image quality for clinical application with the
specified study diffusion protocol. Application of GNC
allowed the use of system A gradients at this site for quanti-
tative studies, in fact reducing the ADC errors in the phan-
tom studies to the lowest level of all equipment
configurations investigated.
Our human studies demonstrated the magnitude of
GN effects in breast imaging, and also the high degree of
variability between scanner configurations. The effects
resulting from spatial offsets in the RL and AP directions
dominated those of offsets in the SI direction, in particular
when longitudinal changes in ADC were measured. We did
not observe a reduction in the relative spread of ADC values
on an individual-ROI basis, even in cases of extended ROIs
with a large spread in GNC values, nor on a site-basis. This
would indicate that the intrasubject and intersubject ADC
variability is large compared to the GNC effects.18 This
may be partly explained by our use of whole tumor multi-
slice ROIs, versus single-slice tumor ROIs which have been
used in other studies evaluating ADC in breast cancer.19,20
Further work is under way on optimizing ROI definition
for treatment response studies, which could better demon-
strate the improvements in accuracy obtained with GNC.
Although our study focused on absolute ADC measurement,
we note that GN effects may also be of significant interest
in relative measurement, eg, when normalizing diseased tis-
sue ADC to normal tissue ADC, or for diagnostic tests for
malignancy.
A limitation of this study is the relatively small num-
ber of gradient systems tested due primarily to the software
restriction to GE scanners. Further work with either
manufacturer-independent correction schemes, or with pro-
prietary GNC programs from the other manufacturers of
FIGURE 7: Absolute change in measured ADC response
(DADCET5percent change of the mean tumor ADC between
MR1 and MR2) with application of GNC plotted versus differ-
ence in (a) the off-axis (combined AP and RL) distance and (b)
the z-axis (SI) distance from magnet isocenter of the respective
MR1 and MR2 ROIs. On average, each 11 cm change in off-
axis position of the tumor ROI is seen to result in an apparent
increase in the measured ADC response of 2.36% (CI 2.05,
2.67). No significant changes were observed due to changes in
z-axis position.
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MRI scanners, is needed to fully map out the extent of the
variability in GN ADC errors across multicenter clinical
breast cancer trials. Extension to higher field strengths is
also needed due to the increasing use of 3.0T scanners for
breast imaging. In addition, this study looked only at a sin-
gle type of ROI definition for measuring tumor ADC
change. The effects of GNC on the measurement of change
in ADC with treatment with different ROI definition
parameters still need to be investigated.
In conclusion, this study illustrates the benefits of
applying GNC to multicenter breast diffusion studies for
more accurate quantification of ADC. If GNC is not avail-
able, the results show the need in longitudinal studies to
avoid switching between scanner configurations, including
receiver coil and multiple gradient modes, for sequential
exams on a given patient. GNC will need to be applied in
order to eliminate a significant source of error when com-
bining results from multiple sites for analysis.
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